Hemangiomas of the liver are benign (non-cancerous) tumors that can cause a variety of medical problems, including pain, bleeding, and even liver failure. Surgery is often the only option for treating these tumors, but it can be complicated and risky. Fortunately, new research is exploring non-surgical treatment options for hemangiomas of the liver, offering hope to patients who may otherwise have no other choice.
A hemangioma is a benign tumor of the liver that is made up of a collection of blood vessels. It is typically found in children and is usually asymptomatic (without symptoms). However, in some cases, the tumor can cause symptoms such as abdominal pain, nausea, vomiting, or jaundice. In rare cases, a hemangioma can cause complications, such as bleeding, infection, or liver failure.
Hemangiomas of the liver are typically diagnosed through imaging tests such as ultrasound, CT scan, or MRI. Once a hemangioma is detected, the doctor may recommend a biopsy or other tests to confirm the diagnosis and assess the size and location of the tumor. Traditionally, the only treatment option for hemangiomas of the liver has been surgery. However, surgery can be risky and complicated, and it may not be an option for some patients. Fortunately, new research is exploring non-surgical treatment options for hemangiomas of the liver, offering hope to patients who may otherwise have no other choice.
There are several non-surgical treatment options available for hemangiomas of the liver. One of the most promising treatments is embolization, which involves injecting a substance into the blood vessels that feed the tumor, cutting off its blood supply and causing it to shrink. Embolization is less invasive than surgery and has fewer risks and side effects. Another non-surgical treatment option is cryoablation, which involves freezing the tumor with a probe. This treatment has been found to be effective in shrinking hemangiomas of the liver and can be done in an outpatient setting. In addition, there are several medications that can be used to treat hemangiomas of the liver. These include corticosteroids, which can reduce the size of the tumor, and interferon-alpha, which can help to shrink the tumor and reduce symptoms.
Non-surgical treatments for hemangiomas of the liver can have risks and side effects, just like any other medical procedure. Embolization, for example, can cause pain, infection, and nerve damage. Cryoablation can cause pain, swelling, and bleeding. Medications can cause side effects such as nausea, headaches, and fatigue. It is important to discuss all of the risks and side effects of any treatment option with your doctor before proceeding.
Hemangiomas of the liver can cause serious medical problems and traditionally, surgery has been the only treatment option. However, new research is exploring non-surgical treatment options, such as embolization, cryoablation, and medications, offering hope to patients who may otherwise have no other choice. While these treatments can be effective, they can also have risks and side effects, so it is important to discuss all of the options with your doctor before proceeding.
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation